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background:  Coronary embolism (CE) is an entity that is recognized as an important non-arteriosclerotic cause of acute myocardial infarction 
(AMI). However, there is little information on its clinical characteristics, including underlying causes. Atrial fibrillation (AF) is associated with systemic 
thromboembolism, and the CHADS2 and CHA2DS2-VASc scores are known to be useful for risk stratification. Thus, we investigated the clinical 
features of CE and assessed the potential usefulness of the CHADS2 or CHA2DS2-VASc score for predicting CE.
methods: We studied consecutive 1955 patients with AMI (1407 males, 548 females, mean age 68±12 [SD] years) hospitalized between 2001 
and 2012. CE was diagnosed on following criteria: angiographic demonstration of abrupt coronary artery occlusion without any other atherosclerotic 
findings; preceding history of embolic risk factors; and evidence of fresh thrombus without arteriosclerotic components.
results: The overall prevalence of CE in AMI was 1.8% (n=35, 21 males, 14 females, mean age 64±14 years). Compared with the remaining 
1920 Non-CE AMI patients, CE patients were characterized as lower incidence of risk factors and lower peak creatine phosphokinase (p<0.05). 
Simultaneous systemic emboli were seen in 9 patients (26%). There was no significant difference in which coronary artery was involved. In CE group, 
26 patients (74%) had AF. However, only 8 (31%) out of 26 AF patients were treated with vitamin K antagonists (VKAs) and had a median PT-INR 
value of 1.37 (range, 0.95-1.76) at the onset of AMI. Importantly, among 22 CE patients with nonvalvular AF (NVAF), 11 patients (50%) had a 
CHADS2 score of 0 or 1. When those particular patients were re-evaluated by newer CHA2DS2-VASc score, 8 out of 11 (64%) were categorized into a 
higher risk category (≥ 2) that would benefit from VKA therapy.
Conclusion: AF is one of the underlying causes of CE when associated with inadequate anticoagulation. The CHA2DS2-VASc score provides reliable 
risk stratification with a superior ability to predict thromboembolism in the coronary arteries.
